Longitudinally monitoring of P‐III‐NP, IGF‐I, and GH‐2000 score increases the probability of detecting two weeks’ administration of low‐dose recombinant growth hormone compared to GH‐2000 decision limit and GH isoform test and micro RNA markers

2018 ◽  
Vol 11 (3) ◽  
pp. 411-421 ◽  
Author(s):  
Mikael Lehtihet ◽  
Hasanuzzaman Bhuiyan ◽  
Abigayle Dalby ◽  
Magnus Ericsson ◽  
Lena Ekström
Keyword(s):  
Growth Hormone ◽  
Low Dose ◽  
Micro Rna ◽  
Recombinant Growth Hormone ◽  
Decision Limit ◽  
Igf I

Standard and low-dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature

2004 ◽  
Vol 60 (2) ◽  
pp. 163-168 ◽  
Author(s):  
J. C. Blair ◽  
C. Camacho-Hübner ◽  
F. Miraki Moud ◽  
S. Rosberg ◽  
C. Burren ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Low Dose ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Idiopathic Short Stature ◽  
Spontaneous Growth ◽  
Igf I

Recombinant growth hormone and insulin-like growth factor I do not alter gonadotrophin stimulation of the baboon testis in vivo

1994 ◽  
Vol 131 (4) ◽  
pp. 405-412 ◽  
Author(s):  
Bronwyn A Crawford ◽  
David J Handelsman
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Insulin Like Growth Factor ◽  
Recombinant Growth Hormone ◽  
Factor I ◽  
Igf I ◽  
Growth Factor I ◽  
Human Primate ◽  
Stimulation Of

Crawford BA, Handelsman DJ. Recombinant growth hormone and insulin-like growth factor I do not alter gonadotrophin stimulation of the baboon testis in vivo. Eur J Endocrinol 1994;131:405–12. ISSN 0804–4643 In vitro studies indicate a physiological role for insulin-like growth factor I (IGF-I) in paracrine regulation of testicular function and recent clinical studies suggest a potential role for growth hormone (GH) and/or IGF-I in the treatment of hypogonadotrophic states in males. This study aimed to examine the effects of pretreatment with recombinant human GH (rhGH) or rhIGF-I on the response to gonadotrophins of the non-human primate testis in vivo. Using a balanced Latin square design with repeated measures, six prepubertal male hamadryas baboons (Papio hamadryas hamadryas) were treated in a cross-over sequence for periods of 18 days with daily im injections of rhGH (0.4 IU·kg−1 · day−1), rhIGF-I (0.1 mg·kg−1 · day−1) or saline with a 2-week washout period between each treatment. A single im injection of hCG (1500 IU) increased serum testosterone (p = 0.0002) but neither rhGH nor rhIGF-I influenced the timing or magnitude of this response (p > 0.5). A single im dose of FSH (75 IU) stimulated immunoreactive inhibin (p = 0.01) but also was unaffected in magnitude or timing by pretreatment with rhGH or rhIGF-I (p> 0.2). Circulating IGF-I levels were increased independently by hCG (p = 0.01) and FSH (p < 0.0001) administration. These findings indicate that neither GH nor IGF-I pre-treatment enhance acute gonadal responses to gonadotrophin stimulation of the prepubertal non-human primate testis in vivo. These findings suggest that GH or IGF-I treatment of hypogonadotrophic men without somatotrophin deficiency is unlikely to be beneficial. David J Handelsman, Andrology Unit, Royal Prince Alfred Hospital, Departments of Medicine and Obstetrics and Gynaecology, University of Sydney, Sydney 2006, Australia

scholarly journals Administration of bovine, porcine and equine growth hormone to the horse: effect on insulin-like growth factor-I and selected IGF binding proteins

2001 ◽  
Vol 171 (1) ◽  
pp. 163-171 ◽  
Author(s):  
SS De Kock ◽  
JP Rodgers ◽  
BC Swanepoel ◽  
AJ Guthrie
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Insulin Like Growth Factor ◽  
Protein Markers ◽  
Recombinant Growth Hormone ◽  
Igf Binding Proteins ◽  
Thoroughbred Horses ◽  
Igf I ◽  
Igf Binding ◽  
Time Required

This study investigated the biochemical effects of administration of three types of recombinant growth hormone (GH; somatotropin) to the Thoroughbred horse. Equine or bovine or porcine GH was administered at a recommended dosage to 3-5-year old Thoroughbred geldings, for up to 21 days. It was shown that, in addition to equine GH, bovine and porcine GH were active in the horse; however, porcine GH caused injection-site reactions that were so serious that administration had to be terminated. The concentrations of a range of GH-related serum protein markers were determined before, during and after the administration period. Because of the short half-life of GH itself, the objective was to identify GH-related markers that showed changes in concentration and which could be used as indicators of the abuse of these hormones. Among the possible markers identified, serum total insulin-like growth factor (IGF)-I was shown to be the most promising, increasing to 270% of the basal concentration for equine GH administration. After GH administration, IGF-I took longer to attain baseline concentrations than the time required for GH concentrations to recover to normal. The concentration obtained from the administration significantly exceeded natural concentrations for IGF-I, as was determined from a population of more than 2000 Thoroughbred horses in three continents. The concentrations of serum free IGF-I and IGF binding protein 3 (IGFBP-3) were also shown to be significantly affected by equine and bovine GH.

scholarly journals Case Report: Human Recombinant Growth Hormone Therapy in a DSH Cat Presented With Dwarfism

2021 ◽  
Vol 8 ◽  
Author(s):  
Martina Načeradská ◽  
Kateřina Návojová Horáčková ◽  
Michaela Fridrichová
Keyword(s):  
Growth Hormone ◽  
Case Report ◽  
Growth Factor ◽  
Serum Level ◽  
Liver Enzymes ◽  
Growth Hormone Therapy ◽  
Nasal Discharge ◽  
Recombinant Growth Hormone ◽  
Igf I ◽  
Human Recombinant Growth Hormone

A 6-month-old kitten, male, domestic shorthair cat was presented with dwarfism, ocular and nasal discharge, and Ascaris infestation. Congenital hyposomatotropism was diagnosed on the basis of serum level of insulin-like growth factor-1 (IGF-I). The cat was treated with human recombinant growth hormone for 9 weeks. After that, his liver enzymes became elevated, and the therapy was discontinued. His IGF-I levels were normal at the end of the therapy. Normal IGF-I was present 3 months after discontinuation of therapy with human recombinant growth hormone and even half a year after the discontinuation. All other comorbidities were addressed with the therapy. The cat is now the size of normal cats, living with the first author.

Sign in / Sign up

Export Citation Format

Share Document